| Literature DB >> 30241318 |
Anna Walentukiewicz1, Anna Lysak-Radomska2, Joanna Jaworska3, Krzysztof Prusik4, Katarzyna Prusik5, Jakub Antoni Kortas6, Marcin Lipiński7, Anna Babinska8, Jedrzej Antosiewicz9, Ewa Ziemann10.
Abstract
The aim of the study was to verify if coupling 12 weeks of vitamin D supplementation and Nordic walking training favoured lowering the homocysteine (Hcy) level. Ninety-four elderly women were divided into three groups: Nordic walking (NW), supplemented (SG) and control (CG). The NW and SG groups received a weekly dose of 28,000 IU of vitamin D3. A blood analysis was performed at baseline, 1h after the first training session and at the end of the experiment. The amino acid profile (methionine and cysteine) and homocysteine concentration were determined. Additionally, the concentration of myokine was assessed. The first session of NW training reduced serum homocysteine, particularly among women with baseline homocysteine above 10 µmol·L-1: 12.37 ± 2.75 vs. 10.95 ± 3.94 µmol·L-1 (p = 0.05). These changes were accompanied by shifts in the cysteine (p = 0.09) and methionine (p = 0.01) concentration, regardless of the Hcy concentration. Twelve weeks of training significantly decreased the homocysteine (9.91 ± 2.78, vs. 8.90 ± 3.14 µmol·L-1, p = 0.05) and ferritin (94.23 ± 62.49 vs. 73.15 ± 47.04 ng·mL-1, p = 0.05) concentrations in whole NW group. Also, in the NW group, ferritin correlated with the glucose level (r = 0.51, p = 0.00). No changes in the myokine levels were observed after the intervention. Only the brain-derived neurotrophic factor dropped in the NW (42.74 ± 19.92 vs. 31.93 ± 15.91 ng·mL-1, p = 0.01) and SG (37.75 ± 8.08 vs. 16.94 ± 12.78 ng·mL-1, p = 0.00) groups. This study presents a parallel decrease of homocysteine and ferritin in response to regular training supported by vitamin D supplementation.Entities:
Keywords: brain-derived neurotrophic factor (BDNF); cysteine; methionine; physical training
Mesh:
Substances:
Year: 2018 PMID: 30241318 PMCID: PMC6210625 DOI: 10.3390/ijerph15102064
Source DB: PubMed Journal: Int J Environ Res Public Health ISSN: 1660-4601 Impact factor: 3.390
Figure 1Study design.
Characteristics of the participants before and after the applied procedure.
| Nordic Walking | Supplemented Group | Control Group | Baseline | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Baseline | After 12w |
| Baseline | After 12w |
| Baseline | After 12w |
|
| |
| Age (years) | 67.8 ± 5.4 | 66.9 ± 6.2 | 68.2 ± 6.7 | 0.71 | ||||||
| Body-Weight (kg) | 68.7 ± 9.8 | 69.2 ± 9.1 | 0.11 | 69.2 ± 10.1 | 70.3 ± 10 | 0.00 | 72.4 ± 12.1 | 73.2 ± 11.8 | 0.48 | 0.34 |
| BMI (kg m−2) | 26.3 ± 3.9 | 26.5 ± 3.7 | 0.06 | 26.4 ± 3.5 | 26.8 ± 3.7 | 0.20 | 27.4 ± 3.9 | 27.9 ± 4.1 | 0.10 | 0.43 |
| Fat (kg) | 23.9 ± 7.4 | 24.4 ± 7.5 | 0.35 | 25.1 ± 7.3 | 25.9 ± 7.7 | 0.11 | 27.2 ± 7.9 | 27.6 ± 8.3 | 0.75 | 0.21 |
| Fat (%) | 34.2 ± 6.4 | 34.7 ± 7.6 | 0.37 | 35.5 ± 6.7 | 36.1 ± 7.1 | 0.33 | 36.7 ± 6.7 | 35.7 ± 8.6 | 0.37 | 0.28 |
| TBW (kg) | 32.8 ± 2.9 | 32.9 ± 3.7 | 0.91 | 32.5 ± 3.7 | 32.7 ± 3.8 | 0.90 | 33.1 ± 4.9 | 33.5 ± 4.8 | 0.33 | 0.81 |
| FFM (kg) | 44.7 ± 4 | 44.8 ± 5 | 0.93 | 44.2 ± 5 | 44.6 ± 5.1 | 0.87 | 45.1 ± 6.6 | 45.6 ± 6.5 | 0.41 | 0.80 |
Values are means (±SD); 12w—12 weeks, baseline—differences between groups at baseline, BMI—body mass index, Fat—fat mass, Fat%—percentage of body fat, TBW—total body water, FFM—free fat mass, all participants n = 94; NW group n = 33; SG group n = 27, CG group n = 34.
Figure 2Changes in cysteine and methionine levels between pre (I) and 1 h after (II) exercise for all participants (white-black stripes) and subgroups with a baseline homocysteine level under 10 µmol·L−1 (white) and over 10 µmol·L−1 (black).
The effect of the first and last single training session of Nordic Walking on immunological response.
| Variable | Before Training | 1 h after Training | Confidence Interval | ||
|---|---|---|---|---|---|
| −95% | +95 | ||||
| Homocysteine (µmol·dL−1) | 9.91 (2.78) | 8.70 (2.31) | 0.01 * | −2.16 | −0.27 |
| hsCRP (mg·L−1) | 2.60 (2.21) | 2.50 (1.80) | 0.53 | −0.67 | 0.38 |
| IL-6 (pg·mL−1) | 1.32 (0.68) | 2.19 (1.29) | 0.01 * | 0.19 | 1.43 |
| BDNF (ng·mL−1) | 42.74 (19.92) | 44.43 (18.81) | 0.96 | −8.68 | 10.00 |
| Irisin (ng·mL−1) | 12.00 (4.44) | 12.66 (4.68) | 0.46 | −1.14 | 2.47 |
|
| |||||
| Homocysteine (µmol·dL−1) | 8.90 (3.14) | 9.17 (2.97) | 0.46 | −0.97 | 0.45 |
| hsCRP (mg·L−1) | 2.82 (3.04) | 2.45 (6.31) | 0.34 | −1.15 | 0.41 |
| IL-6 (pg·mL−1) | 1.59 (0.78) | 2.26 (1.02) | 0.00 * | 0.43 | 0.94 |
| BDNF (ng·mL−1) | 31.93 (15.91) | 26.16 (13.03) | 0.04 * | −12.65 | −0.1 |
| Irisin (ng·mL−1) | 12.45 (6.31) | 12.84 (5.29) | 0.83 | −1.37 | 1.47 |
Values are means (SD); IL-6—interleukin 6, BDNF—brain-derived neurotrophic factor, hsCRP—High sensitivity of C-Reactive Protein, *—Significantly different to baseline (resting condition), confidence interval calculated for range of change.
Changes induced by the applied procedure in the NW group—training and supplementation, in SP by supplementation and values of control group (CG).
| Nordic Walking | Control Group | Supplemented Group | rANOVA | |||||
|---|---|---|---|---|---|---|---|---|
| Baseline | After 12w | Baseline | After 12w | Baseline | After 12w | Interaction | ηp2 | |
| Homocysteine (µmol·L−1) | 9.91 (2.78) | 8.90 * (3.14) | 8.93 (2.35) | 9.51 (3.42) | 9.85 (3.20) | 9.35 (2.69) | 0.08 | |
| Ferritin (ng·mL−1) | 94.23 (62.49) | 73.15* (47.04) | 127.94 (84.94) | 117.05 (87.51) | 137.85 (81.88) | 124.68 (72.11) | 0.03 | |
| Glucose (mg·dL−1) | 96.64 (12.25) | 95.06 (12.05) | 101.88 (12.33) | 98.29 (10.47) | 99.69 (13.62) | 98.54 (13.64) | 0.01 | |
| Vitamin D (ng·mL−1) | 23.01 (9.97) | 59.48* (27.61) | 24.64 (11.61) | 22.11 (9.52) | 27.37 (8.14) | 63.29 * (14.25) | 0.51 | |
| BDNF (ng·mL−1) | 42.74 (19.92) | 31.93 * (15.91) | 33.52 (12.61) | 28.96 (12.86) | 37.75 (8.08) | 16.94 * (12.78) | 0.11 | |
| Irisin (ng·mL−1) | 12.00 (4.44) | 12.45 (6.31) | 11.66 (4.06) | 11.89 (3.71) | 12.17 (7.62) | 11.30 (6.51) | 0.02 | |
| IL-6 (pg·mL−1) | 1.32 (0.68) | 1.59 (0.78) | 1.89 (0.98) | 1.86 (1.56) | 2.66 (1.38) | 3.11 (1.92) | 0.01 | |
| hsCRP (mg·L−1) | 2.60 (2.21) | 2.82 (3.04) | 3.73 (3.31) | 2.75 (3.18) | 2.01 (1.92) | 2.15 (1.97) | 0.06 | |
Values are means (SD). Interaction—Group x time interaction, partial eta squared (ηp2) values are provided to estimate the effect sizes of the repeated measurment analyses of variance (rANOVAs). *—Significant differences after 12 weeks, p < 0.05, 12w—12 weeks.
Figure 3Changes in the resting homocysteine concentration in groups induced by the applied procedure. (A) I—at baseline, II—after 12weeks in NW, control and supplemented groups. (B) Analysis only in the NW Group; marked columns—all participants from the NW group, white columns—participants from the NW group with a baseline homocysteine ≤10 µmol·L−1, black columns—participants from the NW group with a baseline homocysteine >10 µmol·L−1, I—at baseline, II—after 12cweeks of NW training.
Figure 4Correlation between glucose and ferritin levels recorded after the 12 weeks of the experiment.
Figure 5Correlation between ferritin and hsCRP at the baseline and in response to 12 weeks of Nordic Walking training in elderly women in a group with a baseline homocysteine < 10 µmol·L−1], (A) baseline, (B) after 12 weeks of training.